Clinical Research Directory
Browse clinical research sites, groups, and studies.
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
Sponsor: Imperial College London
Summary
The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form. This is represented by a surrogate for improved mitochondrial efficiency with reduction in myocardial lactate levels (produced by inefficient myocardial glycolysis, prevalent in the ventricles of patients with pulmonary hypertension), which can be measured by 31P-magnetic resonance spectroscopy (31P-MRS).
Official title: Myocardial Metabolic Flux in Patients With Pulmonary Arterial Hypertension (PAH) in Response to GLP-1 Agonist Therapy: a Physiological Study Using 31-Phosphorus MR Spectroscopy
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-10-01
Completion Date
2029-04-01
Last Updated
2026-07-30
Healthy Volunteers
No
Conditions
Interventions
GLP-1 agonist
Semaglutide